John T. Lee, PhD, MBA profile page

Dr. John Lee is the global head of cell and gene therapy at SK pharmteco, and a leader in the field of cell and gene therapy. With more than 25 years of expertise, he has a proven track record in advancing innovative therapies across small and large molecules, as well as cell-based therapeutics. Lee has held key roles at The Wistar Institute, Janssen Pharmaceuticals and GlaxoSmithKline. At Janssen, he spearheaded development of the Cell Therapy Platform team, driving discovery and development for a series of CAR-T programs, including the FDA-approved CARVYKTI® (ciltacabtagene autoleucel). Lee has published dozens of articles on CAR-T and gene therapy, reflecting his extensive research in these areas. He earned his PhD from the Brody School of Medicine at East Carolina University, an MBA from Penn State University, and a BSc from Indiana University of Pennsylvania.